NATIONAL HOSPITAL ORGANIZATION OSAKA NATIONAL HOSPITAL

Ono Pharma to Present Positive Phase 2 Data for Tirabrutinib in PCNSL and ONO-4578 in Rectal Cancer at ASCO 2025

- Ono Pharmaceutical will present positive results from the Phase 2 PROSPECT study of tirabrutinib for relapsed or refractory primary central nervous system lymphoma at ASCO 2025 in Chicago. - The company will also showcase data on ONO-4578, an investigational EP4 antagonist, in combination with nivolumab for locally advanced resectable rectal cancer during a poster session. - These presentations represent significant progress in Ono's oncology pipeline, reinforcing their commitment to developing innovative treatment options for patients with difficult-to-treat cancers.